Issue #4 · May 31, 2026 · ArbLens Weekly

Canada Said Yes. China Said Wait.

ICA clears Zijin/Allied Gold — the first major Chinese acquisition past Ottawa's national security review since 2022. But Beijing's NDRC is now the risk. Plus: STB pauses NSC, AXTA hostile bid rejected, Tiptree closes Fortegra.

57
Active Deals
2.4%
Median Spread
$646B
Total Value
13
Closing <60 Days
This Week's Top Moves
$AAUC +26%
Canada clears Zijin/Allied Gold — first major Chinese acquisition past Ottawa since 2022
Investment Canada Act approval received May 29 — the Canadian-side process is now largely complete for Zijin's C$5.5B acquisition of Allied Gold. The remaining overhang is China-side: the FT reported China's NDRC is questioning the premium Zijin is paying, and geopolitical risk persists. Outside date extended to July 29. The 26% spread reflects Beijing risk, not Ottawa risk.
Full analysis on ArbLens →
$NSC +15%
STB pauses UNP/NSC merger review for the second time
The Surface Transportation Board paused the $85B Union Pacific/Norfolk Southern merger on May 28, calling the amended application "unclear or underdeveloped." NSC fell 5.4%, UNP fell 4.2%. A coalition of BNSF, CPKC, Teamsters, Farm Bureau, and the American Chemistry Council actively opposes. The formal review hasn't even started — outside date is January 2028.
Full analysis on ArbLens →
$AXTA +26%
AkzoNobel rejected a hostile €73/share bid from Nippon + Sherwin-Williams
AkzoNobel disclosed May 27 that it rejected a €73/share all-cash bid from Nippon Paint and Sherwin-Williams — Nippon's second attempt. AKZOY surged 20%. The wide spread reflects deal-termination risk: if Nippon succeeds in acquiring AkzoNobel, the Axalta merger terminates (€150M break fee) and AXTA trades back to standalone value.
Full analysis on ArbLens →
$TIPT
Tiptree closed its $1.65B Fortegra sale — now what?
Fortegra closed May 29. Tiptree authorized a $20M share buyback — only 3% of its market cap against $23.80 pro-forma book value. Stock at $18.24, up ~6% since our Special Situations post. The 30% NAV discount persists. The question now is whether management returns the cash or empire-builds.
Read the original deep dive →
From the Blog
Special Situations · May 25
Tiptree: The 40% NAV Discount
Published before the Fortegra close. $23.80 book value, $16.96 price. Three scenarios: capital return, partial return, empire build. Stock up ~6% since publication.
Weekly · Issue #3 · May 23
The June Gauntlet: 14 Deals, $35B, 5 Weeks
June is the busiest month in merger arb this year. WONDF, UNF June 11 dual binary, WBD targeting close. Full breakdown of every near-term catalyst.
New Deals Added This Week

$D — Dominion Energy / NextEra Energy — 0.8138 NEE shares + cash ($46B, largest utility merger in US history)
$RAMP — LiveRamp / Publicis Groupe — $38.50 cash ($2.5B, data + AI strategy)
$CPRX — Catalyst Pharma / Angelini Pharma — $31.50 cash ($4.1B, Blackstone-backed)
$XOMA — XOMA Royalty / Ligand Pharmaceuticals — $39 cash + CVR (Janssen/TREMFYA litigation upside)

Live spreads, spread history charts, and full deal analysis on all 57 active deals.

View All 57 Deals on ArbLens →
📬

Get weekly merger arb insights delivered to your inbox — spreads, regulatory updates, and what to watch next.

For informational purposes only. Nothing here constitutes investment advice. Merger arbitrage involves significant risk including deal failure and loss of capital. Data sourced from public filings and third-party sources.